CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
warfarindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000517
NCT00000517Phase 3Completed
CompareCT.gov

Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)

Massachusetts General Hospital·interventional·Posted Oct 28, 1999·Updated Apr 10, 2014

In Brief

A Phase 3 clinical trial evaluating warfarin for Arrhythmia and 7 related conditions. Completed.

Detailed Summary

To determine the benefits and risks of oral anticoagulant therapy in reducing embolic stroke and systemic emboli in patients with atrial fibrillation without rheumatic heart disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArrhythmia, Atrial Fibrillation, Cardiovascular Diseases, Cerebral Embolism and Thrombosis, Cerebrovascular Disorders, Heart Diseases, Thrombophlebitis, Cerebrovascular Accident
Countries--
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
1985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartJul 1, 1985
Primary CompletionJun 1, 1991
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 26.7 years ago

Interventions

warfarindrug